Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, reinforcing its potential as an effective treatment option while also allowing ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on February 8, 2025, the Compensation Committee granted ...

The National Kidney Foundation (NKF) has awarded Roger Rodby, MD, Professor of Medicine, Division of Nephrology at Rush University Medical Center, the Donald W. Seldin Award. The distinguished honor ...

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

Kidney inflammation caused by SLE is referred to as lupus nephritis (LN), and it is estimated that between 40% and 50% of all SLE patients will develop LN that requires treatment over the course ...

Q32 Bio (NASDAQ:QTTB – Get Free Report) was downgraded by equities researchers at Piper Sandler from an “overweight” rating to a “neutral” rating in a research note issued on Tuesday, MarketBeat ...